On September 10, MSD announced that its PD-1 inhibitor, Corida®, has been approved by the China National Drug Administration to combine new adjuvant treatment with chemotherapy and continue pabolizumab monotherapy after surgery to treat patients with early-stage high-risk triple-negative breast cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.